570
S. G. Davies et al.
LETTER
{lit.16 [a]D23 +9.4 (c 0.3 in EtOH)}. 1H NMR (400 MHz,
N. G.; Jacob, G. S.; Rademacher, T. W. Proc. Natl. Acad.
Sci. U.S.A. 1988, 85, 9229. (f) Goss, P. E.; Baptiste, J.;
Fernandes, B.; Baker, M.; Dennis, J. W. Cancer Res. 1994,
54, 1450.
CDCl3): d = 0.94 [3 H, t, J = 7.3 Hz, C(3¢)H3], 1.36–2.04 [10
H, m, C(3)H2, C(4)H2, C(5)H2, C(1¢)H2, C(2¢)H2], 2.75–2.86
[1 H, m, C(6)HA], 2.87–3.00 [1 H, m, C(6)HB], 3.40–3.53 [1
H, br m, C(2)H], 9.19 [1 H, br s, NHA], 9.49 (1 H, br s, NHB].
(16) Munchof, M. J.; Meyers, A. I. J. Org. Chem. 1995, 60, 7084.
(17) Data for (R)-d-Coniceine Hydrochloride (37·HCl)
(2) Holmes, A. B.; Smith, A. L.; Williams, S. F. J. Org. Chem.
1991, 56, 1393.
(3) (a) Pilli, R. A.; Zanotto, P. R.; Böckelmann, M. A.
Tetrahedron Lett. 2001, 42, 7003. (b) Yamazaki, N.;
Dokoshi, W.; Kibayashi, C. Org. Lett. 2001, 3, 193.
(4) Lindsay, K. B.; Pyne, S. G. J. Org. Chem. 2002, 67, 7774.
(5) O’Brien, P.; Porter, D. W.; Smith, N. M. Synlett 2000, 1336.
(6) For a review, see: Davies, S. G.; Smith, A. D.; Price, P. D.
Tetrahedron: Asymmetry 2005, 16, 2833.
Mp 175 °C; [a]D23 –1.5 (c 1.0 in EtOH). IR (KBr): nmax
=
3477 (NH) cm–1. 1H NMR (400 MHz, CD3OD): d = 1.56–
2.35 [10 H, m, C(1)H2, C(2)H2, C(6)H2, C(7)H2, C(8)H2],
2.92–3.22 [3 H, m, C(3)HA, C(5)HA, C(8a)H], 3.55–3.68 [2
H, m, C(3)HB, C(5)HB]. 13C NMR (125 MHz, CD3OD): d =
20.5, 23.5, 24.4, 29.2, 29.5 [C(1), C(2), C(6), C(7), C(8)],
52.8, 53.6 [C(3), C(5)], 68.0 [C(8a)]. HRMS (ESI+): m/z (%)
= 126 (100) [M + H]+. HRMS (ESI+): m/z calcd for C8H16N+
[M + H]+: 126.1283; found: 126.1278.
(7) (a) Davies, S. G.; Kelly, R. J.; Price-Mortimer, A. J. Chem.
Commun. 2003, 2132. (b) Davies, S. G.; Burke, A. J.;
Garner, A. C.; McCarthy, T. D.; Roberts, P. M.; Smith, A.
D.; Rodriguez-Solla, H.; Vickers, R. J. Org. Biomol. Chem.
2004, 2, 1387. (c) Davies, S. G.; Haggitt, J. R.; Ichihara, O.;
Kelly, R. J.; Leech, M. A.; Price Mortimer, A. J.; Roberts,
P. M.; Smith, A. D. Org. Biomol. Chem. 2004, 2, 2630.
(d) Abraham, E.; Candela-Lena, J. I.; Davies, S. G.;
Georgiou, M.; Nicholson, R. L.; Roberts, P. M.; Russell, A.
J.; Sánchez-Fernández, E. M.; Smith, A. D.; Thomson, J. E.
Tetrahedron: Asymmetry 2007, 18, 2510. (e) Abraham, E.;
Davies, S. G.; Millican, N. L.; Nicholson, R. L.; Roberts,
P. M.; Smith, A. D. Org. Biomol. Chem. 2008, 6, 1655.
(f) Abraham, E.; Brock, E. A.; Candela-Lena, J. I.; Davies,
S. G.; Georgiou, M.; Nicholson, R. L.; Perkins, J. H.;
Roberts, P. M.; Russell, A. J.; Sánchez-Fernández, E. M.;
Scott, P. M.; Smith, A. D.; Thomson, J. E. Org. Biomol.
Chem. 2008, 6, 1665. (g) Davies, S. G.; Fletcher, A. M.;
Roberts, P. M.; Smith, A. D. Tetrahedron 2009, 65, 10192.
(8) (a) Davies, S. G.; Nicholson, R. L.; Price, P. D.; Roberts,
P. M.; Smith, A. D. Synlett 2004, 901. (b) Davies, S. G.;
Nicholson, R. L.; Price, P. D.; Roberts, P. M.; Savory, E. D.;
Smith, A. D.; Thomson, J. E. Tetrahedron: Asymmetry 2009,
20, 756.
(18) Yamazaki, N.; Dokoshi, W.; Kibayashi, C. Org Lett. 2001,
3, 193.
(19) Within this area, Monterrey et al. have shown that alkylation
of N-Cbz protected piperidin-2-yl-acetates with ethyl bromo-
acetate can lead to successful ring closure by removal of the
N-Cbz protecting group in a tandem hydrogenolysis–
hydrogenation step to give the corresponding hexahydro-
indolizin-3-one; see: Monterrey, I. M. G.; González-Muñiz,
R.; Herranz, R.; Garcia-López, M. T. Tetrahedron 1995, 51,
2729.
(20) The anti-configuration of the alkylation was assigned on
the basis of the established preferential anti-alkylations of
lithium b-amino enolates, see: (a) Davies, S. G.; Walters,
I. A. S. J. Chem. Soc., Perkin Trans. 1 1994, 1129.
(b) Ledoux, S.; Célérier, J.-P.; Lhommet, G. Tetrahedron
Lett. 1999, 40, 9019.
(21) Data for (1R,8aR)-1-(Hydroxymethyl)octahydro-
indolizine (40)
[a]D23 –35.8 (c 0.50 in EtOH). 1H NMR (400 MHz, CDCl3):
d = 1.13–1.37 (2 H, m), 1.40–1.69 (3 H, m), 1.74–1.87 (4 H,
m), 1.90–2.13 (3 H, m), 3.05–3.40 [2 H, m, C(3)HA, C(5)HA],
3.46 [1 H, dd, J = 10.2, 2.4 Hz, C(1¢)HA], 3.86 [1 H, dd, J =
10.2, 2.8 Hz, C(1¢)HB], 3.95 (1 H, br s, OH). 13C NMR (100
MHz, CDCl3): d = 24.1, 25.3, 25.4, 26.7 [C(2), C(6), C(7),
C(8)], 41.0 [C(1)], 53.6, 53.9 [C(3), C(5)], 64.6 [C(1¢)], 66.2
[C(8a)]. HRMS (ESI+): m/z (%) = 156 [M + H]+.
(22) Both diastereomers of 1-(hydroxymethyl)octahydro-
indolizidine (40) have previously been reported, see:
(a) Nagao, Y.; Dai, W.; Ochiai, M.; Tsukagoshi, S.; Fujitalc,
E. J. Org. Chem. 1990, 55, 1148. (b) Pandey, G.;
Lakshmaiah, G.; Gadre, S. M. Indian J. Chem., Sect. B: Org.
Chem. Incl. Med. Chem. 1996, 35, 91. (c) Bertrand, S.;
Hoffmann, N.; Pete, J. Eur. J. Org. Chem. 2000, 2227.
(23) Some discrepancies exist between the reported characteri-
sation data for 40 and its epimer; these will be highlighted in
a forthcoming publication from this laboratory. However,
our synthesis unambiguously confirms the relative and
absolute configuration of 40.
(9) Davies, S. G.; Díez, D.; Dominguez, S. H.; Garrido, N. M.;
Kruchinin, D.; Price, P. D.; Smith, A. D. Org. Biomol. Chem.
2005, 3, 1284.
(10) x-Hydroxy-a,b-unsaturated ester 13 was prepared in
55% yield [96:4 E/Z ratio] via the one-pot treatment of
d-valerolactone with DIBAL-H, tert-butyl 2-(diethoxy-
phosphoryl)acetate and BuLi at –78 °C. See ref. 9 for details.
(11) (a) Enders, D.; Wiedemann, J. Liebigs Ann. 1997, 4, 699.
(b) Molander, G. A.; Harris, C. R. J. Org. Chem. 1997, 62,
7418. (c) Li, N.; Piccirilli, J. A. J. Org. Chem. 2004, 69,
4751.
(12) Holmes, A. B.; Smith, A. L.; Williams, S. F. J. Org. Chem.
1991, 56, 1393.
(13) For a related example, see ref. 11a.
(14) b-Amino aldehydes are known to be unstable with respect to
retro-Michael reactions; see: Carruthers, W.; Moses, R. C.
J. Chem. Soc., Perkin Trans. 1 1988, 2251.
(15) Data for (S)-Coniine Hydrochloride (34·HCl)
Mp 208 °C (lit.16 mp 214 °C); [a]D23 +9.2 (c 0.33 in EtOH)
Synlett 2010, No. 4, 567–570 © Thieme Stuttgart · New York